Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn ’s disease

Short-term efficacy and safety of brazikumab (MEDI2070), a human monoclonal antibody and anti-p19 subunit inhibitor of interleukin-23, was demonstrated in a phase 2a trial in patients with moderate-to-severe a...

Source: BMC Gastroenterology - December 20, 2023 Category: Gastroenterology Authors: Silvio Danese, Andrew Beaton, Elizabeth A. Duncan, Anne-Kristina Mercier, Jessica Neisen, Henrik Seth, Sofia Zetterstrand and Bruce E. Sands Tags: Research Source Type: research